Indian biopharmaceutical company Biocon has decided to withdraw its plans to launch generic versions of Novo Nordisk’s popular diabetes and weight-loss drugs, Ozempic and Wegovy, in China. Amit Kaptain, head of Biocon’s commercial API division, confirmed the decision during an industry event in Shanghai, stating that the Chinese market is already saturated with Continue Reading
